Cite
HARVARD Citation
McDermott, D. et al. (n.d.). 2622 A Phase I/II study to assess the safety and efficacy of pazopanib (paz) and pembrolizumab (pembro) in patients (pts) with advanced renal cell carcinoma (aRCC). European journal of cancer. pp. S519-S520. [Online].